Watch this video with Professor Gian Maria Rossolini on ATLAS : Antimicrobial Testing Leadership and Surveillance. Professor Rossolini covers the practical aspects of using the online ATLAS platform. A new, comprehensive, fully-searchable database available worldwide to support antibiotic resistance surveillance.
AMS Part III | How is the clinical & economic impact of an AMS program measured?
Mark Gilchrist, MPharm, MSc, IPres, FFRPS, Consultant Pharmacist, Infectious Diseases, UK presents on the topic of Antimicrobial Stewardship. How is the Clinical and Economic impact of an AMS program measured?
A pathogen, commonly known as a germ - is a living particle that causes disease or illness, most often by disrupting the normal functioning of the human body. But there's not just one kind. There are viruses, bacteria, fungi, prions and more. Download your Field Guide to Germs to learn more.
AMS Part II | How are AMS Programs implemented & What are the main goals?
Mark Gilchrist, MPharm, MSc, IPres, FFRPS, Consultant Pharmacist, Infectious Diseases, UK presents on the topic of Antimicrobial Stewardship. How are AMS programs implemented and what are the main goals?
A Superbug Problem | When routine surgeries turn dangerous
S. aureus is a common bacterium found on the skin and in the nose that is usually harmless. This all changes if it enters the body through cuts and grazes. To compound this in recent years, potentially life-threatening, antibiotic-resistant strains have emerged known as methicillin-resistant Staphylococcus aureus (MRSA).
In this short video, Dr Matthew Dryden, MD, FRCPath, Consultant, Department of Microbiology and Infection from Hampshire Hospitals speaks about how we can collectively combat the spread of Antimicrobial Resistance.
In this short video, Dr Matthew Dryden, MD, FRCPath, Consultant, Department of Microbiology and Infection from Hampshire Hospitals speaks about Antimicrobial Resistance and the steps we can take to protect our future.